NZ598883A - Crystalline forms of a parp inhibitor compound - Google Patents

Crystalline forms of a parp inhibitor compound

Info

Publication number
NZ598883A
NZ598883A NZ598883A NZ59888310A NZ598883A NZ 598883 A NZ598883 A NZ 598883A NZ 598883 A NZ598883 A NZ 598883A NZ 59888310 A NZ59888310 A NZ 59888310A NZ 598883 A NZ598883 A NZ 598883A
Authority
NZ
New Zealand
Prior art keywords
theta
degrees
following peaks
compound
diffraction pattern
Prior art date
Application number
NZ598883A
Other languages
English (en)
Inventor
Michael Kress
Linli He
Laurent Courvoisier
Martin J Jacobs
Joseph Petraitis
Stephen Bierlmaier
R Curtis Haltiwanger
Dale R Mowrey
Robert E Mckean
R Scott Field
Mehran Yazdanian
Michael Christie
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43033463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ598883(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of NZ598883A publication Critical patent/NZ598883A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
NZ598883A 2009-08-26 2010-08-25 Crystalline forms of a parp inhibitor compound NZ598883A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23718009P 2009-08-26 2009-08-26
PCT/US2010/046671 WO2011028580A1 (en) 2009-08-26 2010-08-25 Novel forms of a multicyclic compound

Publications (1)

Publication Number Publication Date
NZ598883A true NZ598883A (en) 2014-09-26

Family

ID=43033463

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ598883A NZ598883A (en) 2009-08-26 2010-08-25 Crystalline forms of a parp inhibitor compound

Country Status (19)

Country Link
US (1) US8633314B2 (enExample)
EP (1) EP2470540B1 (enExample)
JP (3) JP2013503173A (enExample)
KR (1) KR20120092100A (enExample)
CN (1) CN102482282A (enExample)
AU (1) AU2010289746B2 (enExample)
BR (1) BR112012004053A2 (enExample)
CA (1) CA2772328C (enExample)
CL (1) CL2012000478A1 (enExample)
DK (1) DK2470540T3 (enExample)
EA (1) EA020756B1 (enExample)
ES (1) ES2572652T3 (enExample)
IL (1) IL218132B (enExample)
MX (1) MX2012002456A (enExample)
MY (1) MY156873A (enExample)
NZ (1) NZ598883A (enExample)
SG (1) SG178852A1 (enExample)
UA (1) UA110604C2 (enExample)
WO (1) WO2011028580A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503173A (ja) * 2009-08-26 2013-01-31 セファロン、インク． 多環系化合物の新規形態
CA2967828A1 (en) 2014-11-26 2016-06-02 Cephalon, Inc. Crystalline forms of parp inhibitors
HRP20240136T1 (hr) 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
AU2018246214B2 (en) 2017-03-27 2021-07-08 Merck Sharp & Dohme Llc Niraparib compositions
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
CN109632555B (zh) * 2018-12-28 2021-07-27 上海新黄河制药有限公司 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
US20060276497A1 (en) 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
CN101316592A (zh) * 2005-08-24 2008-12-03 伊诺泰克制药公司 茚并异喹啉酮类似物及其用法
WO2008063644A1 (en) 2006-11-20 2008-05-29 Cephalon, Inc. Method of radio-sensitizing tumors using a radio-sensitizing agent
JP2013503173A (ja) * 2009-08-26 2013-01-31 セファロン、インク． 多環系化合物の新規形態

Also Published As

Publication number Publication date
CL2012000478A1 (es) 2012-11-05
EP2470540A1 (en) 2012-07-04
JP2018035158A (ja) 2018-03-08
MX2012002456A (es) 2012-05-08
CA2772328A1 (en) 2011-03-10
EA020756B1 (ru) 2015-01-30
EA201270315A1 (ru) 2012-08-30
AU2010289746B2 (en) 2016-07-07
JP2016014029A (ja) 2016-01-28
WO2011028580A1 (en) 2011-03-10
MY156873A (en) 2016-04-15
KR20120092100A (ko) 2012-08-20
BR112012004053A2 (pt) 2020-12-08
EP2470540B1 (en) 2016-04-20
AU2010289746A1 (en) 2012-04-12
CA2772328C (en) 2017-06-20
ES2572652T3 (es) 2016-06-01
HK1171750A1 (zh) 2013-04-05
CN102482282A (zh) 2012-05-30
US8633314B2 (en) 2014-01-21
UA110604C2 (uk) 2016-01-25
JP2013503173A (ja) 2013-01-31
SG178852A1 (en) 2012-04-27
DK2470540T3 (en) 2016-08-01
US20120214998A1 (en) 2012-08-23
IL218132A0 (en) 2012-06-28
IL218132B (en) 2018-02-28

Similar Documents

Publication Publication Date Title
ZA200603861B (en) Use of tricyclic compounds as glycine transport inhibitors
CA2781661A1 (en) Ship1 modulators and methods related thereto
AU2022215237B2 (en) Methods of preparing indolinobenzodiazepine derivatives
CN101348483A (zh) 菲并吲哚里西啶衍生物的制备
CN102249998A (zh) 一种制备顺苯磺酸阿曲库铵的方法
Lin et al. Easy access to synthesize isoquinolines from aryl ketoximes and internal alkynes via Iridium (III)-catalyzed CH/NO bond activation
Khalaj Preparation of benzo [4, 5] thiazolo [3, 2-a] chromeno [4, 3-d] pyrimidin-6-one derivatives using MgO-MgAl2O4 composite nano-powder
Mohaqeq et al. A flexible one-pot synthesis of 8, 10-dimethyl-12-aryl-9 H-naphto [1′, 2′: 5, 6] pyrano [2, 3-d] pyrimidine-9, 11-diones catalyzed by ZnO nanoparticles under solvent-free conditions
Khan et al. Synthesis of wilsoniamines A and B
CN101891637A (zh) 一种甘氨酸酯盐酸盐的合成及其母液的处理方法
WO2005090301B1 (en) Crystalline form of atorvastatin hemi calcium
CN106967057A (zh) 一种阿瑞匹坦高效制备工艺
CN102952061B (zh) N-取代吲哚二酮类化合物及其制备方法
CN105218433A (zh) 一种琥珀酸多西拉敏新晶型及其制备方法和应用
CN103709039A (zh) Cu-丝光沸石催化合成没食子酸甲（乙）酯的方法
Bogolubsky et al. One-pot parallel synthesis approach to secondary amines based on the reductive amination of ketones
Komatsuzaki et al. An Anion Receptor Based on Poly-Substituted Cobalticinium Complexes.
CN101891737A (zh) 一种Lewis酸催化氨解合成美洛昔康的方法
CN101130520A (zh) 经非对映异构体盐的外消旋体拆分制备天然(-)-石杉碱甲和非天然(+)-石杉碱甲的新方法
CN101665483B (zh) 一种雷尼酸锶中间体化合物ⅱ的合成方法
Huang et al. An Improved Synthesis of 1, 4, 7-Triazacyclononanes (tacns) and 1, 4, 7, 10-Tetraazacyclododecanes (cyclens)
CN106220625B (zh) 一种盐酸哌仑西平关键中间体的合成方法
AU2005321228A1 (en) Arylpiperazine derivatives and use thereof as 5-HT1A receptor ligands
KR20160105557A (ko) 고순도 올란자핀의 정제 방법
CN103435591A (zh) 胡椒碱的化学合成方法

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 25 AUG 2017 BY WATERMARK PATENT AND TRADE MARKS ATTORNEYS

Effective date: 20150108

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 AUG 2018 BY DENNEMEYER + CO

Effective date: 20170726

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 AUG 2019 BY DENNEMEYER + CO

Effective date: 20180802

LAPS Patent lapsed